- Home
- FWRG vs NRIX Comparison
FWRG vs NRIX Comparison
Compare FWRG & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWRG
- NRIX
- Stock Information
- Founded
- FWRG 1983
- NRIX 2009
- Country
- FWRG United States
- NRIX United States
- Employees
- FWRG N/A
- NRIX N/A
- Industry
- FWRG Restaurants
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- FWRG Consumer Discretionary
- NRIX Health Care
- Exchange
- FWRG Nasdaq
- NRIX Nasdaq
- Market Cap
- FWRG 970.4M
- NRIX 908.0M
- IPO Year
- FWRG 2021
- NRIX 2020
- Fundamental
- Price
- FWRG $16.56
- NRIX $12.15
- Analyst Decision
- FWRG Strong Buy
- NRIX Strong Buy
- Analyst Count
- FWRG 10
- NRIX 16
- Target Price
- FWRG $22.20
- NRIX $29.56
- AVG Volume (30 Days)
- FWRG 817.7K
- NRIX 944.3K
- Earning Date
- FWRG 08-05-2025
- NRIX 07-09-2025
- Dividend Yield
- FWRG N/A
- NRIX N/A
- EPS Growth
- FWRG N/A
- NRIX N/A
- EPS
- FWRG 0.17
- NRIX N/A
- Revenue
- FWRG $1,055,701,000.00
- NRIX $88,381,000.00
- Revenue This Year
- FWRG $21.37
- NRIX $34.87
- Revenue Next Year
- FWRG $15.98
- NRIX N/A
- P/E Ratio
- FWRG $97.73
- NRIX N/A
- Revenue Growth
- FWRG 14.43
- NRIX 41.86
- 52 Week Low
- FWRG $12.90
- NRIX $8.18
- 52 Week High
- FWRG $22.71
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- FWRG 48.63
- NRIX 51.32
- Support Level
- FWRG $17.17
- NRIX $12.08
- Resistance Level
- FWRG $18.46
- NRIX $13.00
- Average True Range (ATR)
- FWRG 0.81
- NRIX 0.83
- MACD
- FWRG 0.04
- NRIX -0.01
- Stochastic Oscillator
- FWRG 47.58
- NRIX 28.91
About FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.